Patents by Inventor Christophe Marchand
Christophe Marchand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210139492Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.Type: ApplicationFiled: January 11, 2021Publication date: May 13, 2021Inventors: Linkun An, Christophe Marchand, Yves Pommier
-
Patent number: 10906914Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed Formula I. The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.Type: GrantFiled: January 8, 2016Date of Patent: February 2, 2021Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SUN YAT-SEN UNIVERSITYInventors: Linkun An, Christophe Marchand, Yves Pommier
-
Patent number: 10208035Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: GrantFiled: May 8, 2017Date of Patent: February 19, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, Jr.
-
Publication number: 20180009822Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed Formula I. The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.Type: ApplicationFiled: January 8, 2016Publication date: January 11, 2018Inventors: Linkun An, Christophe Marchand, Yves Pommier
-
Publication number: 20170305904Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: ApplicationFiled: May 8, 2017Publication date: October 26, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, JR.
-
Patent number: 9676771Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: GrantFiled: May 13, 2014Date of Patent: June 13, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, Jr.
-
Patent number: 9399660Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: GrantFiled: April 28, 2015Date of Patent: July 26, 2016Assignees: Purdue Research Foundation, NATIONAL INSTITUTES OF HEALTH (NIH)Inventors: Mark S. Cushman, Yves George Pommier, Peng-Cheng Lu, Christophe Marchand, Keli Agama
-
Publication number: 20160083382Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: ApplicationFiled: May 13, 2014Publication date: March 24, 2016Applicant: The United States of American, as represented by the Sec, Dept. of Health and Human ServicesInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, Jr.
-
Publication number: 20150299246Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: ApplicationFiled: April 28, 2015Publication date: October 22, 2015Applicants: Purdue Research Foundation, THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICESInventors: Mark S. CUSHMAN, Yves George POMMIER, Peng-Cheng LU, Christophe MARCHAND, Keli AGAMA
-
Patent number: 9010395Abstract: A device for laying up a dry preform having an elongated shape includes a punch that reproduces the elongated shape of the dry preform, a depositing assembly, and a mobile carrier that moves at least one of the punch and the depositing assembly. The depositing assembly deposits, onto the punch, a fibrous band including a small amount of binding agent to make up the dry preform having a cross-section with at least two non-coplanar wings. The depositing assembly also includes pressing devices that press the fibrous band, a channel that pre-shapes the fibrous band to have the cross-section, and a calibration device that applies a normal pressure to all surfaces of the dry preform that are opposite from the punch while cooling the pressed portion of the fibrous band to control a thickness of the dry preform having the cross-section.Type: GrantFiled: September 30, 2010Date of Patent: April 21, 2015Assignee: Airbus Operations S.A.S.Inventors: Philippe Blot, Christophe Marchand, Claude Le Bail, Simon Deseur, Jerome Soto
-
Patent number: 8865686Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.Type: GrantFiled: September 29, 2008Date of Patent: October 21, 2014Assignee: The United States of America, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Yves Pommier, Laurent Thibaut, Christophe Marchand
-
Patent number: 8716295Abstract: A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In certain embodiments, the fluoroquinolone derivative or sulfonamide moiety-containing compound is co-administered with a topoisomerase I (TopI) inhibitor.Type: GrantFiled: October 27, 2011Date of Patent: May 6, 2014Inventors: Yves Pommier, Christophe Marchand, Periyasamy Selvam, Thomas Dexheimer, Kasthuraiah Maddali
-
Publication number: 20120328846Abstract: The invention relates to a device and a method for the realization of elongated textile preforms intended for manufacturing load-bearing composite members by means of a method using resin infusion. More specifically, the device and the method, which are the subjects of the invention, are designed for manufacturing substantially circular preforms, intended, for example, for the realization of aircraft fuselage frames or segments of frames. The invention provides a method for depositing gradually and continuously a fibrous tape comprising a small amount of binding agent over the length of an elongated shape to make a preform whose shape comprises at least two non-coplanar wings.Type: ApplicationFiled: September 30, 2010Publication date: December 27, 2012Applicant: AIRBUS OPERATIONS (S.A.S.)Inventors: Philippe Blot, Christophe Marchand, Claude Le Bail, Simon Deseur, Jerome Soto
-
Publication number: 20120289109Abstract: The manufacturing method includes a step of resin transfer moulding, wherein resin is injected (E) in a preform (1), which is placed in a closed mold (2) and said preform (1) is degassed during the whole resin injection operation of this step of resin transfer moulding.Type: ApplicationFiled: May 9, 2012Publication date: November 15, 2012Applicant: AIRBUS OPERATIONS SASInventors: Sébastien GOHIER, Philippe BLOT, Christophe MARCHAND, Maxime PROVOST
-
Publication number: 20120172371Abstract: A method for treating cancer in a subject, comprising administering to a subject having cancer a therapeutically effective amount of (i) a fluoroquinolone derivative that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity or (ii) a sulfonamide moiety-containing compound that inhibits tyrosyl-DNA-phosphodiesterase 1 (Tdp1) activity, thereby treating the cancer in the subject. In certain embodiments, the fluoroquinolone derivative or sulfonamide moiety-containing compound is co-administered with a topoisomerase I (TopI) inhibitor.Type: ApplicationFiled: October 27, 2011Publication date: July 5, 2012Inventors: Yves Pommier, Christophe Marchand, Periyasamy Selvam, Thomas Dexheimer, Kasthuraiah Maddali
-
Patent number: 7776883Abstract: Novel quinoline inhibitors of retroviral integrase, particularly HIV-1 integrase. The quinoline inhibitors are oxoquinolines that can be used for preventing or treating AIDS or HIV infection in a subject.Type: GrantFiled: March 9, 2005Date of Patent: August 17, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Roberto Di Santo, Yves Pommier, Christophe Marchand, Marino Artico, Roberta Costi
-
Publication number: 20100152301Abstract: Treatment of cells or subjects (e.g., humans, animals) carrying or infected with a virus capable of causing an immunodeficiency disease by administration of one or more compounds that inhibit integrase.Type: ApplicationFiled: December 1, 2006Publication date: June 17, 2010Applicant: GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Yves Pommier, Christophe Marchand, Elena Semenova, Allison Johnson
-
Publication number: 20090298934Abstract: The instant invention is directed towards compounds, including diamidines, that inhibit Tdp1 and are useful in the treatment and/or prevention of cancer and parasitic disease.Type: ApplicationFiled: March 27, 2007Publication date: December 3, 2009Applicant: GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETInventors: Yves Pommier, Christophe Marchand
-
Publication number: 20090176747Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.Type: ApplicationFiled: September 29, 2008Publication date: July 9, 2009Applicant: National Institutes of HealthInventors: Yves Pommier, Laurent Thibaut, Christophe Marchand
-
Publication number: 20070219242Abstract: Novel quinoline inhibitors of retroviral integrase, particularly HIV-1 integrase. The quinoline inhibitors are oxoquinolines that can be used for preventing or treating AIDS or HIV infection in a subject.Type: ApplicationFiled: March 9, 2005Publication date: September 20, 2007Inventors: Roberto Di Santo, Yves Pommier, Christophe Marchand, Marino Artico, Roberta Costi